ESPR

+ Watchlist + Portfolio

Esperion Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.00
52-Week Range: $1.21 – $4.18
Market Cap: $819.46M
P/E (TTM): Infinity
EPS (TTM): 0.00
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: 12.04%
Gross Margin: 57.79%
Operating Margin: -8.22%
Profit Margin: -1.77%
Current Ratio: 1.53
Debt/Equity: —
Total Debt: $543.81M
Free Cash Flow: $-49.71M
Revenue Growth: 23.20%
Earnings Growth: —
Enterprise Value: $1.21B

ESPR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$75.47M	$116.33M	$332.31M	$403.13M
Cost of Revenue	$26.97M	$43.27M	$68.60M	$129.22M
Gross Profit	$48.51M	$73.07M	$263.71M	$273.91M
Research & Development	$118.93M	$86.11M	$46.24M	$47.85M
Selling, General & Admin	$109.08M	$142.52M	$163.07M	$165.79M
Operating Expenses	$228.01M	$228.63M	$209.31M	$213.64M
Operating Income	-$179.50M	-$155.56M	$54.40M	$60.27M
EBITDA	-$176.35M	-$150.11M	$7.57M	$63.87M
Pretax Income	-$233.66M	-$209.25M	-$51.74M	-$20.84M
Income Tax	—	$0.00	$0.00	$1.84M
Net Income	-$233.66M	-$209.25M	-$51.74M	-$22.68M
Diluted EPS	-3.52	-2.03	-0.28	-0.11
Diluted Shares	66.41M	103.11M	187.18M	207.87M

ESPR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$124.78M	$82.25M	$144.76M	$167.85M
Receivables	$33.73M	$48.49M	$80.14M	$140.19M
Inventory	$35.20M	$65.62M	$94.49M	$105.12M
Current Assets	$246.68M	$201.06M	$338.00M	$462.57M
Total Assets	$247.94M	$205.80M	$343.82M	$465.89M
Current Liabilities	$92.31M	$156.22M	$246.23M	$300.81M
Long-Term Debt	$259.90M	$261.60M	$237.72M	$249.48M
Total Debt	$260.95M	$266.17M	$297.60M	$252.23M
Total Liabilities	$571.72M	$660.79M	$732.54M	$767.85M
Retained Earnings	-$1.34B	-$1.55B	-$1.60B	-$1.62B
Shareholders' Equity	-$323.78M	-$454.99M	-$388.72M	-$301.96M
Working Capital	$154.38M	$44.84M	$91.77M	$161.76M
Net Debt	$135.12M	$179.35M	$147.53M	$81.63M

ESPR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$174.83M	-$135.49M	-$23.65M	-$13.09M
Capital Expenditure	—	—	-$317.00K	—
Free Cash Flow	-$174.83M	-$135.49M	-$23.97M	-$13.09M
Depreciation & Amortisation	$500.00K	$164.00K	$63.00K	$105.00K
Stock-Based Compensation	$15.21M	$11.96M	$11.99M	$9.87M
Investing Cash Flow	$8.10M	$42.50M	-$317.00K	$0.00
Financing Cash Flow	$32.61M	$50.46M	$86.48M	$36.18M
Dividends Paid	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	-$134.12M	-$42.53M	$62.51M	$23.09M

ESPR Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$65.00M	$82.39M	$87.31M	$168.45M	$80.10M
Cost of Revenue	$31.54M	$28.54M	$41.29M	$27.85M	$34.57M
Gross Profit	$33.46M	$53.84M	$46.02M	$140.59M	$45.53M
Research & Development	$12.56M	$7.24M	$14.13M	$13.93M	$8.99M
Selling, General & Admin	$43.00M	$39.51M	$41.85M	$41.43M	$43.12M
Operating Expenses	$55.55M	$46.75M	$55.98M	$55.36M	$52.11M
Operating Income	-$22.10M	$7.09M	-$9.96M	$85.23M	-$6.58M
EBITDA	-$21.00M	$7.79M	-$9.26M	$86.33M	-$5.37M
Pretax Income	-$40.45M	-$12.72M	-$31.33M	$63.67M	-$25.20M
Net Income	-$40.45M	-$12.72M	-$31.33M	$61.83M	-$25.20M
Diluted EPS	-0.21	-0.02	-0.16	0.22	-0.10
Diluted Shares	196.13M	197.55M	200.74M	284.57M	251.35M

ESPR Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$114.63M	$86.06M	$92.45M	$167.85M	$156.16M
Receivables	$81.29M	$107.75M	$118.98M	$140.19M	$132.35M
Inventory	$99.32M	$114.47M	$108.54M	$105.12M	$104.21M
Current Assets	$318.78M	$342.60M	$360.46M	$462.57M	$459.46M
Total Assets	$324.03M	$347.08M	$364.02M	$465.89M	$462.53M
Current Liabilities	$270.97M	$298.80M	$359.03M	$300.81M	$300.36M
Long-Term Debt	$238.32M	$243.45M	$248.78M	$249.48M	$250.07M
Total Debt	$297.78M	$302.27M	$306.80M	$252.23M	$252.63M
Total Liabilities	$750.24M	$780.59M	$815.38M	$767.85M	$770.46M
Retained Earnings	-$1.64B	-$1.65B	-$1.69B	-$1.62B	-$1.65B
Shareholders' Equity	-$426.21M	-$433.51M	-$451.36M	-$301.96M	-$307.93M
Working Capital	$47.81M	$43.80M	$1.43M	$161.76M	$159.10M
Net Debt	$178.36M	$212.16M	$211.20M	$81.63M	$93.91M

ESPR Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$22.63M	-$31.42M	-$4.29M	$45.24M	-$27.72M
Capital Expenditure	—	—	—	—	-$189.00K
Free Cash Flow	-$22.63M	-$31.42M	-$4.29M	$45.24M	-$27.91M
Depreciation & Amortisation	$26.00K	$27.00K	$26.00K	$26.00K	$27.00K
Stock-Based Compensation	$2.46M	$2.67M	$2.35M	$2.39M	$2.50M
Investing Cash Flow	$0.00	$0.00	$0.00	$0.00	-$189.00K
Financing Cash Flow	-$7.50M	$2.85M	$10.67M	$30.16M	$16.22M
Dividends Paid	$0.00	$0.00	$0.00	$0.00	—
Net Change in Cash	-$30.13M	-$28.57M	$6.39M	$75.41M	-$11.69M

Market Snapshot

About

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). The company has developed oral non-statin LDL-C lowering medicines for patients who cannot achieve their cholesterol goals with statins alone or who are statin-intolerant. Esperion's commercial products provide additional treatment options for managing cardiovascular risk through lipid modification. The company continues to conduct clinical research to expand approved indications and develop next-generation cardiovascular therapies.